Renin-Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study.
- 1Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
- 2Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract
Background
Renin-angiotensin system (RAS) inhibitors may influence cancer incidence, but previous findings have been inconsistent. We aimed to evaluate the associations of RAS inhibitor use with overall and site-specific cancer incidence.Materials and methods
Participants receiving antihypertensive treatment without prior invasive cancer (except non-melanoma skin cancer) were identified from the UK Biobank. Individuals with missing covariate data were excluded. Participants were classified as ACEI users, ARB users, or RAS inhibitor non-users, defined as participants receiving antihypertensive medications other than ACEIs or ARBs. Outcomes included overall cancer incidence and site-specific cancers. Inverse probability of treatment-weighted Cox proportional hazards models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results
Among 94,696 participants followed for a mean of 11.5 years, 42,930 were ACEI users, 17,681 were ARB users, and 34,085 were RAS inhibitor non-users. No significant associations were observed between ACEI or ARB use and overall cancer incidence. In site-specific analyses, ARB use showed a modest association with higher prostate cancer incidence compared with ACEI use (HR = 0.90; 95% CI, 0.82-0.99) and RAS inhibitor non-use (HR = 1.14; 95% CI, 1.02-1.27). ACEI use was associated with lower bladder cancer incidence compared with RAS inhibitor non-use (HR = 0.71; 95% CI, 0.54-0.93).Conclusion
RAS inhibitor use was not associated with overall cancer incidence in this large cohort of antihypertensive medication users. Although modest associations were observed between ARB use and prostate cancer incidence and between ACEI use and bladder cancer incidence, these findings should be interpreted cautiously and require confirmation in future studies.
Related
- Large-scale accelerometry-derived physical activity and sedentary behaviour assessmentsin relation to health characteristics and outcomes among participants of the Lifelines Biobank study: rationale and design of the ActiveLIFE cohort study
- A multidimensional proteomic framework of circulating inflammation identifies outcome-specific cardiovascular risk axes in 39,494 UK biobank participants
- Associating a Polygenic Risk Score for Multiple Sclerosis with Brain MRI Metrics and Cognitive Performance in Healthy UK Biobank Participants
- Angiotensin receptor neprilysin inhibitor (ARNI) in right ventricular failure and preserved LV ejection fraction: A systematic review and meta-analysis.
- Pain phenotypes and chronic pain burden are associated with atherosclerotic cardiovascular disease and vascular disease progression in participants with type 2 diabetes: a UK Biobank cohort study with multistate analysis
BibTeX
@article{shi2026reninangiotensin,
title = {{Renin-Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study.}},
author = {Xuyuan Shi and Yi Liu and Zelin Ma and Shuxiao Ma and Zihuai Wang and Min Yi and Lunxu Liu},
journal = {Cancer medicine},
year = {2026},
month = nov,
doi = {10.1002/cam4.72420},
url = {https://europepmc.org/article/MED/42972931},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Renin-Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study.
AU - Xuyuan Shi
AU - Yi Liu
AU - Zelin Ma
AU - Shuxiao Ma
AU - Zihuai Wang
AU - Min Yi
AU - Lunxu Liu
PY - 2026
DA - 2026/11/01
JO - Cancer medicine
DO - 10.1002/cam4.72420
UR - https://europepmc.org/article/MED/42972931
AB - Background Renin-angiotensin system (RAS) inhibitors may influence cancer incidence, but previous findings have been inconsistent. We aimed to evaluate the associations of RAS inhibitor use with overall and site-specific cancer incidence.Materials and methods Participants receiving antihypertensive treatment without prior invasive cancer (except non-melanoma skin cancer) were identified from the UK Biobank. Individuals with missing covariate data were excluded. Participants were classified as ACEI users, ARB users, or RAS inhibitor non-users, defined as participants receiving antihypertensive medications other than ACEIs or ARBs. Outcomes included overall cancer incidence and site-specific cancers. Inverse probability of treatment-weighted Cox proportional hazards models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results Among 94,696 participants followed for a mean of 11.5 years, 42,930 were ACEI users, 17,681 were ARB users, and 34,085 were RAS inhibitor non-users. No significant associations were observed between ACEI or ARB use and overall cancer incidence. In site-specific analyses, ARB use showed a modest association with higher prostate cancer incidence compared with ACEI use (HR = 0.90; 95% CI, 0.82-0.99) and RAS inhibitor non-use (HR = 1.14; 95% CI, 1.02-1.27). ACEI use was associated with lower bladder cancer incidence compared with RAS inhibitor non-use (HR = 0.71; 95% CI, 0.54-0.93).Conclusion RAS inhibitor use was not associated with overall cancer incidence in this large cohort of antihypertensive medication users. Although modest associations were observed between ARB use and prostate cancer incidence and between ACEI use and bladder cancer incidence, these findings should be interpreted cautiously and require confirmation in future studies.
SN - 2045-7634
ER -